Cadila Healthcare has started production of its potential COVID-19 vaccine and is expected to seek emergency use authorization for the same in May or June, reported the company’s managing director. The company aims to make up to 240 million doses in a year.

Government officials have stated that they are waiting for the company to seek approval for ZyCoV-D. Sharvil Patel said that the goal was to produce 10 million doses a month starting from June, taking the annual capacity to 120 million. The rest of the production will come from third-party producers.

This vaccine is a DNA plasmid product. A small part of the viruss genetic code is injected to stimulate the recipient’s immune response. The vaccine is currently designed to be given as a three-dose regimen; however, the company is also carrying out trials on a two-dose regimen… (NDTV – Reuters, April 23, 2021)